Breaking Finance News

Cerus Corporation (NASDAQ:CERS) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has downgraded Cerus Corporation (NASDAQ:CERS) to Sell in a report released on 10/05/2016.

Previously on 7/7/2016, Cantor Fitzgerald released a statement on Cerus Corporation (NASDAQ:CERS) bumped up the target price from $0.00 to $9.00 that suggested an upside of 0.42%.

Yesterday Cerus Corporation (NASDAQ:CERS) traded 0.97% higher at $6.26. CERS’s 50-day average is $6.38 and its two hundred day average is $6.23. With the last stock price close up 0.52% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Volume of trade was down over the average, with 314,192 shares of CERS changing hands under the typical 1,143,150

See Chart Below

Cerus Corporation (NASDAQ:CERS)

With a total market value of $0, Cerus Corporation has with a 52 week low of $4.27 and a 52 week high of $7.64 .

In addition to Zacks Investment Research reporting its stock price target, a total of 4 brokers have issued a research note on Cerus Corporation. The 12-month price target is $9.50 with four brokerages rating the company a strong buy, one brokerage rating the company a buy, zero brokerages rating the company a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Cerus Corporation (NASDAQ:CERS)

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company's INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.